SEC Form 4 · accession 0000899243-18-021415
CRISPR Therapeutics AG · CRSP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Tony W Ho
Officer — See Remarks
Period of report
Aug 1, 2018
Accepted (ET)
Aug 3, 2018 · 5:43 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001674416
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1 | Aug 1, 2018 | M | 37,500 | — | A | 37,500 | D | |
| Common Shares | Aug 2, 2018 | F | 14,631 | $48.43 | D | 22,869 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Aug 1, 2018 | M | 37,500 | D | — | — | Common Shares | 37,500 | 37,500 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
- F2On August 1, 2017, the reporting person was granted 75,000 restricted stock units that vest in two equal annual installments on 8/1/2018 and 8/1/2019.
Remarks
Executive Vice President, Head of Research & Development